References
- Cohen P. The structure and regulation of protein phosphatases. Annu Rev Biochem 1989; 58:453 - 508; http://dx.doi.org/10.1146/annurev.bi.58.070189.002321; PMID: 2549856
- Lambrecht C, Haesen D, Sents W, Ivanova E, Janssens V. Structure, Regulation, and Pharmacological Modulation of PP2A Phosphatases. Methods Mol Biol 2013; 1053:283 - 305; http://dx.doi.org/10.1007/978-1-62703-562-0_17; PMID: 23860660
- Mukhopadhyay A, Tabanor K, Chaguturu R, Aldrich JV. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment. Cancer Biol Ther 2013; 14:962 - 72; http://dx.doi.org/10.4161/cbt.25943; PMID: 24025258
- Modrak DE, Gold DV, Goldenberg DM. Sphingolipid targets in cancer therapy. Mol Cancer Ther 2006; 5:200 - 8; http://dx.doi.org/10.1158/1535-7163.MCT-05-0420; PMID: 16505092
- Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med 2013; 5:105 - 21; http://dx.doi.org/10.1002/emmm.201201283; PMID: 23180565
- Bareford MD, Hamed HA, Allegood J, Cruickshanks N, Poklepovic A, Park MA, Ogretmen B, Spiegel S, Grant S, Dent P. Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. Cancer Biol Ther 2012; 13:793 - 803; http://dx.doi.org/10.4161/cbt.20562; PMID: 22673740